Financials data is unavailable for this security.
View more
Year on year Rohto Pharmaceutical Co Ltd grew revenues 13.48% from 238.66bn to 270.84bn while net income improved 17.29% from 26.38bn to 30.94bn.
Gross margin | 57.76% |
---|---|
Net profit margin | 11.02% |
Operating margin | 14.18% |
Return on assets | 8.42% |
---|---|
Return on equity | 12.69% |
Return on investment | 11.70% |
More ▼
Cash flow in JPYView more
In 2024, Rohto Pharmaceutical Co Ltd increased its cash reserves by 11.42%, or 8.87bn. The company earned 34.27bn from its operations for a Cash Flow Margin of 12.65%. In addition the company used 16.32bn on investing activities and also paid 13.78bn in financing cash flows.
Cash flow per share | 172.87 |
---|---|
Price/Cash flow per share | 21.21 |
Book value per share | 1,129.95 |
---|---|
Tangible book value per share | 882.08 |
More ▼
Balance sheet in JPYView more
Current ratio | 1.77 |
---|---|
Quick ratio | 1.27 |
Total debt/total equity | 0.1779 |
---|---|
Total debt/total capital | 0.1513 |
More ▼
Growth rates in JPY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 22.73% and 17.28%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
Div yield(5 year avg) | 0.90% |
---|---|
Div growth rate (5 year) | 18.61% |
Payout ratio (TTM) | 20.31% |
EPS growth(5 years) | 25.85 |
---|---|
EPS (TTM) vs TTM 1 year ago | 6.47 |
More ▼